STAAR Surgical Company (NASDAQ:STAA) Receives $26.94 Consensus PT from Analysts

Shares of STAAR Surgical Company (NASDAQ:STAA) have been given a consensus recommendation of “Hold” by the thirteen brokerages that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, six have issued a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $26.9444.

A number of research firms have weighed in on STAA. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of STAAR Surgical in a research note on Tuesday, August 4th. Mizuho lifted their target price on STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Weiss Ratings raised STAAR Surgical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 25th. UBS Group initiated coverage on STAAR Surgical in a report on Tuesday, July 28th. They set a “sell” rating and a $20.00 price target for the company. Finally, Stifel Nicolaus increased their price target on STAAR Surgical from $18.00 to $31.00 and gave the company a “hold” rating in a research report on Thursday, May 14th.

STAAR Surgical Price Performance

STAA stock opened at $25.12 on Tuesday. The stock has a market capitalization of $1.25 billion, a PE ratio of -58.42 and a beta of 1.26. The company’s 50-day moving average is $27.11 and its 200-day moving average is $24.01. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.12 and a quick ratio of 4.31. STAAR Surgical has a 1 year low of $15.59 and a 1 year high of $35.87.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The business had revenue of $93.52 million during the quarter, compared to analyst estimates of $78.72 million. During the same period in the previous year, the company posted ($1.10) EPS. The firm’s revenue was up 119.6% compared to the same quarter last year. Equities research analysts expect that STAAR Surgical will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its position in STAAR Surgical by 58.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,669 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 614 shares in the last quarter. Invesco Ltd. boosted its stake in shares of STAAR Surgical by 0.6% in the 3rd quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier’s stock worth $4,055,000 after buying an additional 956 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of STAAR Surgical by 2.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,535 shares of the medical instruments supplier’s stock worth $1,214,000 after buying an additional 1,234 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of STAAR Surgical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after acquiring an additional 1,267 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of STAAR Surgical by 3.7% in the fourth quarter. Deutsche Bank AG now owns 38,586 shares of the medical instruments supplier’s stock valued at $891,000 after acquiring an additional 1,382 shares in the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.